Profitelligence Profitelligence · Filing Ledger Open BMY research →

Form 8-K · Current Report · Filed 2025-11-03

Bristol-Myers Squibb Launches Tender Offer to Purchase Certain Notes

On November 3, 2025, Bristol-Myers Squibb announced the commencement of cash tender offers to purchase certain of its outstanding notes for an aggregate purchase price of up to $7 billion.

Filer
Bristol-Myers Squibb Company BMY · NYSE
Filed
Accession
0001140361-25-040066
CIK
0000014272
Signal
Medium impactHealthcare

Details

The tender offers are subject to specific terms and conditions outlined in the Offer to Purchase. The offers include two pools of notes with different priorities and maximum purchase prices.

Items reported

Item 8.01

Other Events

Share Repurchase Program Announced
Item 9.01

Financial Statements and Exhibits

Exhibits Furnished

Market reaction

Close before filing

$46.07

Next session

-1.0%

Since filing

+41.8%

Latest close

$65.31

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from BMY reporting the same item, with the next session's move:

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is a renowned pharmaceutical corporation engaged in the discovery, development, and distribution of innovative medicines. The company's core focus lies in providing therapeutic solutions for areas such as oncology, immunology, cardiovascular disease, and fibrotic diseases. Founded in 1887 and headquartered in New York City, it has grown into a key player in the global healthcare market, influencing medical advancements and treatment protocols. Bristol-Myers Squibb is pivotal for its groundbreaking contributions to cancer treatment, particularly through its development of immunotherapy drugs, which alter and assist the immune system's ability to fight cancer cells. Additionally, the firm extends its impacts across multiple sectors, affecting industries such as biotechnology, pharmaceuticals, and healthcare. The company's significance is underscored by its extensive research and development investments, often collaborating with research institutions and academic entities worldwide to pioneer new treatments. Such collaborations expand its influence beyond product distribution to shaping future healthcare landscapes. Bristol-Myers Squibb's commitment to innovation and addressing unmet medical needs makes it a prominent entity in the pharmaceutical sector.

Exchange NYSE Industry Drug Manufacturers - General Company website ↗

Never miss another BMY filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts